Damning Testimony from Former GlaxoSmithKline CEO Jean-Pierre Garnier in Paxil Suicide Case

► Former GlaxoSmithKline CEO Jean-Pierre Garnier’s deposition in Paxil suicide case. Garnier says in his testimony that GSK’s way of counting adverse events associated with Paxil hid the suicidal behavior risk.

This deposition was played for the jury in the trial of Dolin v. Smithkline Beecham Corp. (D/B/A GlaxoSmithKline-GSK). The case stems from the alleged paroxetine-induced death of Stewart Dolin, a partner at the law firm Reed Smith. Paroxetine is the brand name version of this medication is called Paxil which was researched, developed, manufactured and marketed by GlaxoSmithKline (“GSK”).

The lawsuit alleges that GSK failed to adequately warn Mr. Dolin’s doctor about Paxil/paroxetine’s association with an increased risk of suicidal behavior in adults of all ages.

According to the lawsuit, when Mr. Dolin was prescribed paroxetine in 2010, the label did not accurately warn physicians of the drug’s association with an increased risk of suicidal behavior in adults, despite GSK’s 2006 analysis showing a statistically significant 6.7 times greater risk in adults of all ages, as well as comparable statistically significant suicidal behavior evidence as far back as 1989 in Paxil’s clinical trials performed for its initial marketing approval.

See our YouTube page for other GSK depositions.

Click here to subscribe to Baum Hedlund’s YouTube Channel

Let’s Connect!